Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Microbiotix Announces Exclusive Worldwide Licensing Agreement for HCV NS5B Non-Nucleoside Polymerase Inhibitors

WORCESTER, Mass., Jan. 2, 2013 /PRNewswire/ -- Microbiotix, Inc., a privately-held, clinical stage biopharmaceutical company engaged in the discovery and development of novel small molecule anti-infective drugs, announced today that it has entered into an exclusive licensing agreement with Merck, known as MSD outside the United States and Canada.

As part of this agreement, Microbiotix gains worldwide rights to develop, manufacture and commercialize MBX-700 and MBX-701 (formerly SCH 900942 and SCH 900188), two non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. MBX-700 is in Phase I clinical testing and MBX-701 is currently in preclinical development. Merck is eligible for milestone payments during development stages of the candidates, and for royalty payments from any resulting products. Specific terms of the agreement were not disclosed.

MBX-700 and MBX-701 are designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase, a clinically validated target that is essential for viral genome replication. In vitro studies have shown MBX-700 to be among the most potent HCV NS5B polymerase inhibitors.

"This agreement with Merck significantly strengthens our antiviral portfolio," said Terry L. Bowlin, PhD, President & CEO, Microbiotix. "We believe MBX-700 and MBX-701 have great potential as potent ingredients in future combination drug therapy. Our preclinical studies have demonstrated high potency while the Phase I clinical study has shown MBX-700 to be safe and well-tolerated."

"Merck remains committed to the development of therapies for the treatment of hepatitis C," said Eliav Barr, vice president, Infectious Diseases Project Leadership and Management, Merck Research Laboratories. "Our discovery programs have identified a number of well-characterized candidates targeting hepatitis C. Outlicensing deals, such as this one, allow Merck to harness potential value from these assets while ensuring they are developed to their full potential."

About Hepatitis C
Hepatitis C, which primarily affects the liver, is an infectious disease caused by the hepatitis C virus (HCV). HCV infection becomes chronic in 75%-85% of cases and, if left untreated, can lead to chronic liver disease, liver cancer or death. It is estimated that 170 million people worldwide are chronically infected with the hepatitis C virus.

About Microbiotix, Inc.
Microbiotix, Inc., located in Worcester, MA, is a biopharmaceutical company focused on the discovery and development of proprietary small molecule drugs that target serious infectious diseases. The Company's lead therapeutic compound, MBX-700, is a non-nucleoside inhibitor of the HCV NS5B polymerase. In vitro studies have shown MBX-700 to be among the most potent HCV polymerase inhibitors. MBX-700 is in Phase I clinical testing. MBX-701, a non-nucleoside inhibitor also targeting the HCV NS5B polymerase, is in preclinical development. The Company's second clinical compound, MBX-400, a novel agent for the treatment of human cytomegalovirus, is also in Phase I clinical testing.

SOURCE Microbiotix, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
I'll be heading to Southeast Asia immediately following our upcoming @CloudExpo @ThingsExpo in Santa Clara. I'll rekindle some previous business relationships I had when I lived in the region in 2009-2012. I'll also investigate new ways to bring the messages of socio-economic growth th...
On August 28th, Samsung and LG announced their latest generation of smartwatches in separate press releases. The Samsung report flaunts its Gear S, a smartwatch with a curved screen that measures a full two-inches long. Capabilities of the watch include providing notifications from soc...
My favorite writer, Gil Press, sums it up with, “It’s Official: The Internet Of Things Takes Over Big Data As The Most Hyped Technology” where he talks about how Gartner released its latest Hype Cycle for Emerging Technologies, and how big data has moved down the “trough of disillusion...
Internet of @ThingsExpo Silicon Valley announced today its first 20 all-star speakers and sessions for its upcoming event, which will take place November 4-6, 2014, at the Santa Clara Convention Center in Silicon Valley. @ThingsExpo, the first and largest IoT event in the world, debute...
Last week I was both learning and speaking at the The Internet of @ThingsExpo in New York City. I taught a session on the subject of IoT, Code Halos and Digital Transformation Strategies. Then I had the privilege of interviewing Microsoft's mobile and IoT guru Nick Landry (Twitter @Act...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE